Breaking News Instant updates and real-time market news.

HOG

Harley-Davidson

$49.25

1.73 (3.64%)

, PII

Polaris Industries

$127.66

4.24 (3.44%)

04:55
11/29/17
11/29
04:55
11/29/17
04:55

Wedbush leisure analyst holds an analyst/industry luncheon meeting

Leisure Analyst Haridman discusses the aging U.S. population and what it means for the Harley Davidson Company at a Luncheon Meeting being held in Boston on November 29.

HOG

Harley-Davidson

$49.25

1.73 (3.64%)

PII

Polaris Industries

$127.66

4.24 (3.44%)

  • 29

    Nov

HOG Harley-Davidson
$49.25

1.73 (3.64%)

10/18/17
MSCO
10/18/17
NO CHANGE
Target $54
MSCO
Overweight
Morgan Stanley wonders if its time for Harley-Davidson to 'think more radically'
Morgan Stanley analyst Adam Jonas said that expectations heading into Harley-Davidson's Q3 report were quite low and noted that its comparisons will "get way easier" from here. However, the slowing bike market may not, which leads him to question if it is time for the company "to think more radically." In a note titled "Messy Quarter: Too Soon to Consider Strategic Options?," Jonas noted the continued demographic pressures the company faces and said his Overweight rating on Harley shares reflects a "relatively attractive valuation" in an LBO framework. He keeps an Overweight rating and $54 price target on Harley-Davidson shares.
10/20/17
ARGS
10/20/17
UPGRADE
Target $53
ARGS
Buy
Harley-Davidson upgraded to Buy from Hold at Argus
Argus analyst David Coleman upgraded Harley-Davidson to Buy with a $53 price target due to market share gains and a strengthening of its product mix, despite industrywide pricing pressure. Coleman said Harley continues to reduce older motorcycle inventory and has begun an ambitious effort to launch 100 new models by 2027. The analyst is impressed with new models and styles and which should enable most buyers to get the look, sound, and feel that they want directly from the sales floor, without costly upgrades. Coleman does not believe Harley-Davidson's discounted valuation is warranted based on increasing market share, improved mix, and potential to attract new customers.
10/20/17
10/20/17
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. lululemon (LULU) upgraded to Buy from Neutral at Citi with analyst Paul Lejuez saying recent market concerns around Amazon.com (AMZN) competition, denim trends and weather are overblown, Lejuez tells investors in a research note. 2. TechnipFMC (FTI) upgraded to Buy from Hold at Gabelli with analyst Simon Wong saying its well positioned to gain market share in subsea production systems, maintains a strong balance sheet, and believes concerns over its EPC business are overblown. 3. Harley-Davidson (HOG) upgraded to Buy from Hold at Argus with analyst David Coleman citing market share gains and a strengthening of its product mix, despite industry-wide pricing pressure. 4. Philip Morris (PM) upgraded to Buy from Hold at Societe Generale. 5. Owens Corning (OC) upgraded to Neutral from Sell at Citi. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
11/17/17
UBSW
11/17/17
NO CHANGE
Target $47
UBSW
Neutral
Harley-Davidson decline in October may not reflect true demand, says UBS
UBS analyst Robin Farley noted Harley-Davidson said October sales were down double digits, one of the worst months of the year. she believes it is possible the decline may overstate how poor demand really is and said it is possible the company may have miscalculated while trying to reduce dealer inventory. Farley maintained her Neutral rating and $47 price target on Harley-Davidson shares.
PII Polaris Industries
$127.66

4.24 (3.44%)

09/15/17
BMOC
09/15/17
NO CHANGE
BMOC
Polaris Industries business performing well, says BMO Capital
After attending Polaris' investor meeting, BMO Capital analyst Gerrick Johnson says that the company's comments and outlook on its business and the macro economy have improved significantly. The analyst says that retail sales of the company's 2017 and orders for its 2018 products "are tracking ahead of plan." As a result, he is confident that his "high-on- the-Street 2017 estimates will be achieved." He raised his price target on the stock to $115 from $110 and recommends buying the shares.
10/25/17
BMOC
10/25/17
DOWNGRADE
Target $132
BMOC
Market Perform
Polaris Industries downgraded to Market Perform from Outperform at BMO Capital
BMO Capital analyst Gerrick Johnson downgraded Polaris Industries to Market Perform while raising his price target for the shares to $132 from $115. The analyst finds it "prudent to harvest some profits" with the shares up 50% since January. Johnson, however, is encouraged by the progress Polaris is making to improve and grow its business.
10/25/17
WELS
10/25/17
NO CHANGE
Target $115
WELS
Market Perform
Polaris Industries price target raised to $115 from $93 at Wells Fargo
Wells Fargo analyst Tim Conder raised his price target for Polaris Industries to $115 from $93 following share strength post Q3 report driven by short covering, and better than anticipated company/industry ORV recovery. The analyst reiterates a Market Perform rating on the shares.
10/25/17
RHCO
10/25/17
NO CHANGE
Target $115
RHCO
Hold
Polaris Industries price target raised to $115 from $84 at SunTrust
SunTrust analyst Michael Swartz raised his price target on Polaris Industries to $115 after a solid Q3 report, noting signs suggesting that the industry may be stabilizing after a challenging 18-24 months. Swartz adds that the company's clearance/incentive programs have resulted in share gain. The analyst maintains a Hold rating, as Polaris PE valuation of 22.5-times is above its 16-22 times historical range.

TODAY'S FREE FLY STORIES

GME

GameStop

$18.97

-0.23 (-1.20%)

10:10
12/11/17
12/11
10:10
12/11/17
10:10
Options
In the money put buyers in GameStop »

In the money put buyers…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KURA

Kura Oncology

$14.90

0.75 (5.30%)

10:07
12/11/17
12/11
10:07
12/11/17
10:07
Hot Stocks
Kura Oncology findings supoort tipifarnib development in bone marrow cancers »

Kura Oncology reported…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BIVV

Bioverativ

$51.47

0.76 (1.50%)

10:05
12/11/17
12/11
10:05
12/11/17
10:05
Hot Stocks
Bioverativ data shows extended dosing with Alprolix provides HepB protection »

Bioverativ and Swedish…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XENT

Intersect ENT

$28.60

-1.325 (-4.43%)

10:05
12/11/17
12/11
10:05
12/11/17
10:05
Recommendations
Intersect ENT analyst commentary  »

Intersect ENT approval…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Jan

CTL

CenturyLink

$15.62

0.9451 (6.44%)

10:04
12/11/17
12/11
10:04
12/11/17
10:04
Technical Analysis
Technical View: CenturyLink higher on Commonwealth of Pennsylvania contract »

The stock was last up…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BMRN

BioMarin

$81.99

1.09 (1.35%)

10:03
12/11/17
12/11
10:03
12/11/17
10:03
Hot Stocks
BioMarin highlights new results for valoctocogene roxaparvovec at ASH »

BioMarin Pharmaceutical…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Jan

  • 28

    Feb

ABBV

AbbVie

$96.13

0.18 (0.19%)

10:02
12/11/17
12/11
10:02
12/11/17
10:02
Hot Stocks
AbbVie: Ibrutinib inhibited pre-germinal center B cells in trial »

AbbVie announced new data…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ALXN

Alexion

$114.46

7.68 (7.19%)

10:02
12/11/17
12/11
10:02
12/11/17
10:02
Hot Stocks
Alexion reports results from Phase 1b/2 studies of ALXN1210 »

Alexion Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

10:01
12/11/17
12/11
10:01
12/11/17
10:01
General news
JOLTS Job Openings data reported »

October JOLTS Job…

CELG

Celgene

$106.09

3.36 (3.27%)

10:00
12/11/17
12/11
10:00
12/11/17
10:00
Options
Sizable put spread in Celgene as shares see strength »

Sizable put spread in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jan

  • 25

    Mar

MARK

Remark Holdings

$8.84

1.43 (19.30%)

09:59
12/11/17
12/11
09:59
12/11/17
09:59
Conference/Events
Remark Holdings management to meet with Roth Capital »

Meeting to be held in San…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

CTL

CenturyLink

$15.47

0.795 (5.42%)

, FTR

Frontier Communications

$9.75

0.6 (6.56%)

09:55
12/11/17
12/11
09:55
12/11/17
09:55
Options
Early notable gainers among liquid option names on December 11th »

Notable gainers among…

CTL

CenturyLink

$15.47

0.795 (5.42%)

FTR

Frontier Communications

$9.75

0.6 (6.56%)

SWN

Southwestern Energy

$5.72

0.225 (4.10%)

MNK

Mallinckrodt

$22.64

0.34 (1.52%)

WYNN

Wynn Resorts

$159.54

0.62 (0.39%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

  • 11

    Dec

  • 14

    Dec

ECR

Eclipse Resources

$2.36

0.21 (9.77%)

09:55
12/11/17
12/11
09:55
12/11/17
09:55
Conference/Events
Eclipse Resources to hold a conference call »

Management discusses the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

XLE

Energy Select Sector SPDR

$69.57

0.29 (0.42%)

09:54
12/11/17
12/11
09:54
12/11/17
09:54
Technical Analysis
Technical View: Energy Select Sector SPDR leads on the upside »

The Energy Select Sector…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NKE

Nike

$61.50

0.195 (0.32%)

09:51
12/11/17
12/11
09:51
12/11/17
09:51
Upgrade
Nike rating change  »

Follow-up: Nike upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Dec

IBB

iShares Nasdaq Biotechnology Index

$106.07

2.02 (1.94%)

09:50
12/11/17
12/11
09:50
12/11/17
09:50
Technical Analysis
Technical View: iShares Nasdaq Biotechnology Index breaks out »

The iShares Nasdaq…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AKS

AK Steel

$5.46

0.13 (2.44%)

09:50
12/11/17
12/11
09:50
12/11/17
09:50
Options
Interest in AK Steel Mar 7 calls continues »

Interest in AK Steel Mar…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ONCE

Spark Therapeutics

$73.38

2.82 (4.00%)

09:48
12/11/17
12/11
09:48
12/11/17
09:48
Conference/Events
Spark Therapeutics to hold a pharmaceutical update conference call »

Management reviews the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Dec

  • 12

    Jan

NKE

Nike

$61.67

0.365 (0.60%)

09:47
12/11/17
12/11
09:47
12/11/17
09:47
Upgrade
Nike rating change  »

Nike upgraded to Positive…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Dec

09:45
12/11/17
12/11
09:45
12/11/17
09:45
General news
JOLTS Job Openings to be reported at 10:00 »

October JOLTS Job…

IOTS

Adesto Technologies

$7.00

-0.45 (-6.04%)

09:44
12/11/17
12/11
09:44
12/11/17
09:44
Conference/Events
Adesto Technologies management to meet with Roth Capital »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

  • 14

    Dec

AGIO

Agios Pharmaceuticals

$60.97

0.14 (0.23%)

09:42
12/11/17
12/11
09:42
12/11/17
09:42
Conference/Events
Agios Pharmaceuticals to hold an investor meeting »

Investor Meeting where…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

KMB

Kimberly-Clark

09:41
12/11/17
12/11
09:41
12/11/17
09:41
Technical Analysis
Technical View: Kimberly-Clark falls in early trading, analyst action »

The stock was last down…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AKS

AK Steel

, CELG

Celgene

$106.09

3.36 (3.27%)

09:40
12/11/17
12/11
09:40
12/11/17
09:40
Options
Unusually active option classes on open December 11th »

Unusual total active…

AKS

AK Steel

CELG

Celgene

$106.09

3.36 (3.27%)

GME

GameStop

CTL

CenturyLink

X

U.S. Steel

ORCL

Oracle

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Dec

  • 18

    Jan

  • 25

    Mar

09:40
12/11/17
12/11
09:40
12/11/17
09:40
General news
Fed funds futures are flat to lower ahead of Wednesday's FOMC »

Fed funds futures are…

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.